{"disease":{"id":"acute-intermittent-porphyria-aip","name":"acute intermittent porphyria aip"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03547297","title":"INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP","phase":"","overall_status":"TERMINATED","enrollment_count":212,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT03505853","title":"A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}